Faculty profile

David Hedley

ResearcherMedical OncologyUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

David Hedley

Researcher

Medical Oncology

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
7 publications in the last five years, latest in 2025.
Senior (last) author on 1 recent paper, a sign of leading a research group.
Principal investigator on 3 research grants (3 CIHR), most recently in 2014.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

658

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Quantitative Assessment Adjuvant Chemotherapy Hypoxia Metastasis Pancreatic Cancer

Latest papers

Emergence of a senescent and inflammatory pulmonary CD4+ T cell population prior to lung allograft failure.
Science advances · 2025
Detailed cellular and spatial characterization of chronic lung allograft dysfunction using imaging mass cytometry.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2025
The CD8+ T cell content of transbronchial biopsies from patients with a first episode of clinically stable grade A1 cellular rejection is associated with future chronic lung allograft dysfunction.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2024

All 54 publications

Latest funding

Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
CIHR · 2023 · Co-investigator
$994,500
Nuclear-targeted X-ray activated photodynamic therapy of pancreatic cancer
CIHR · 2018 · Co-investigator
$371,024
Mechanistic studies of macrophages and the tumour microenvironment as immunologic barriers to therapy in pancreatic ductal adenocarcinoma
CIHR · 2018 · Co-investigator
$1,059,525

All 12 grants and awards

54 publications.

Emergence of a senescent and inflammatory pulmonary CD4+ T cell population prior to lung allograft failure.

Moshkelgosha S, Levy L, Safavi S, Karunagaran S, Wilson G, Renaud-Picard B, Madu G, Ramchandani R, Oliver J, Watanabe T, Bei KF, Joe B, Li Q, Huszti E, Cheung M, Hedley D, Yeung J, Keshavjee S, Martinu T, Juvet S

Science advances2025

DOI: 10.1126/sciadv.adp9052 PMID: 40117366

Detailed cellular and spatial characterization of chronic lung allograft dysfunction using imaging mass cytometry.

Renaud-Picard B, Moshkelgosha S, Berra G, Cheung M, Hwang D, Hedley D, Juvet S, Martinu T

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2025

DOI: 10.1016/j.healun.2024.09.023 PMID: 39368678

The CD8+ T cell content of transbronchial biopsies from patients with a first episode of clinically stable grade A1 cellular rejection is associated with future chronic lung allograft dysfunction.

Beber SA, Moshkelgosha S, White M, Zehong G, Cheung M, Hedley D, Levy L, Samuels J, Renaud-Picard B, Hwang D, Martinu T, Juvet S

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2024

DOI: 10.1016/j.healun.2024.06.001 PMID: 38852935

A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma

Aung KL, McWhirter E, Welch S, Wang L, Lovell S, Stayner L-A, Ali S, Malpage A, Makepeace B, Ramachandran M

Journal of Gastrointestinal Oncology202235 citations

DOI: 10.21037/jgo-22-86

Combined Targeting of the Glutathione and Thioredoxin Antioxidant Systems in Pancreatic Cancer.

Fazzari F, Chow S, Cheung M, Barghout SH, Schimmer AD, Chang Q, Hedley D

ACS pharmacology & translational science2022Senior author

DOI: 10.1021/acsptsci.2c00170 PMID: 36407947

Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer.

Doherty MK, Tam VC, McNamara MG, Jang R, Hedley D, Chen E, Dhani N, Tang P, Sim HW, O'Kane GM, DeLuca S, Wang L, Pedutem T, Knox JJ

British journal of cancer2022

DOI: 10.1038/s41416-022-01903-6 PMID: 35869145

Impact of Definitive Chemoradiation on Quality-of-Life Changes for Patients With Anal Cancer: Long-term Results of a Prospective Study.

Hosni A, Ringash J, Han K, Liu ZA, Brierley JD, Wong RKS, Dawson LA, Cummings BJ, Krzyzanowska MK, Chen EX, Hedley D, Knox JJ, Easson AM, Lindsay P, Craig T, Kim J

Diseases of the colon and rectum2022

DOI: 10.1097/dcr.0000000000002385 PMID: 35067501

NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4.

Jain P, Dvorkin-Gheva A, Mollen E, Malbeteau L, Xie M, Jessa F, Dhavarasa P, Chung S, Brown KR, Jang GH, Vora P, Notta F, Moffat J, Hedley D, Boutros PC, Wouters BG, Koritzinsky M

Science advances2021

DOI: 10.1126/sciadv.abf7114 PMID: 33962950

An Iodinated DAPI-Based Reagent for Mass Cytometry.

Rana R, Chang Q, Bassan J, Chow S, Hedley D, Nitz M

Chembiochem : a European journal of chemical biology2021

DOI: 10.1002/cbic.202000369 PMID: 32897623

Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or β-particle emitting, 177Lu.

Aghevlian S, Cai Z, Hedley D, Winnik MA, Reilly RM

EJNMMI radiopharmacy and chemistry2020

DOI: 10.1186/s41181-020-00111-y PMID: 33169241

Something wrong or missing on this profile? Suggest a correction

David Hedley

Research

Latest papers

Latest funding

Emergence of a senescent and inflammatory pulmonary CD4+ T cell population prior to lung allograft failure.

Detailed cellular and spatial characterization of chronic lung allograft dysfunction using imaging mass cytometry.

The CD8+ T cell content of transbronchial biopsies from patients with a first episode of clinically stable grade A1 cellular rejection is associated with future chronic lung allograft dysfunction.

A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma

Combined Targeting of the Glutathione and Thioredoxin Antioxidant Systems in Pancreatic Cancer.

Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer.

Impact of Definitive Chemoradiation on Quality-of-Life Changes for Patients With Anal Cancer: Long-term Results of a Prospective Study.

NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4.

An Iodinated DAPI-Based Reagent for Mass Cytometry.

Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or &#x3b2;-particle emitting, 177Lu.

Frequent collaborators

Neesha Dhani

Steven Gallinger

Ming-Sound Tsao

Amit Oza

Faiyaz Notta

Lisa Wang

Gregory Pond

John Kim

Tereza Martinu

Stephen Juvet

Mark Nitz

Michael Milosevic

Jason Moffat

David Hwang

Gavin Wilson

Kathy Han

Monika Krzyzanowska

Sebastien Hotte

Elaine McWhirter

Geoffrey Liu

Tony Panzarella

Carol Swallow

Mark Minden

Shaf Keshavjee

Richard Tozer

Sukhbinder Dhesy-Thind

Raimond Wong

Holger Hirte

Steven Narod

John Goffin

Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or β-particle emitting, 177Lu.